Back to Search
Start Over
Assessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoring-Mass Spectrometry.
- Source :
-
Proteomics. Clinical applications [Proteomics Clin Appl] 2020 Jul; Vol. 14 (4), pp. e1900095. Date of Electronic Publication: 2020 Feb 16. - Publication Year :
- 2020
-
Abstract
- Purpose: Plasma markers that enable diagnosis in the early stage of lung cancer is not discovered. A liquid chromatography multiple reaction monitoring-mass spectrometry (LC-MRM-MS) assay for identifying potential early marker proteins for lung adenocarcinoma is developed.<br />Experimental Design: LC-MRM-MS assay is used for measuring the level of 35 candidate peptides in plasma from 102 lung adenocarcinoma patients (including n = 50, 16, 24, and 12 in stage I, II, III, and IV, respectively.) and 84 healthy controls. Stable isotope labeled standard peptides are synthesized to accurately measure the amount of these proteins.<br />Results: Seven proteins are able to distinguish stage I patients from controls. These proteins are combined in to a protein marker panel which improve the sensitivity to discriminate stage I patients from controls with cross-validated area under the curve = 0.76. Besides, it is found that low expression of eukaryotic initiation factor 4A-I and high expression of lumican show significantly poor prognosis in overall survival (p = 0.012 and 0.0074, respectively), which may be used as prognostic biomarkers for lung cancer.<br />Conclusions and Clinical Relevance: Proteins highlighted here may be used for early detection of lung adenocarcinoma or therapeutics development after validation in a larger cohort.<br /> (© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
Details
- Language :
- English
- ISSN :
- 1862-8354
- Volume :
- 14
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Proteomics. Clinical applications
- Publication Type :
- Academic Journal
- Accession number :
- 32012456
- Full Text :
- https://doi.org/10.1002/prca.201900095